ACTIVE: TSHA-102 REVEAL paediatric gene-therapy study – Canada, UK and USA
Posted: Thu Sep 03, 2026 10:48 pm
Status: Active, not recruitingStudy: REVEAL paediatric study of TSHA-102
Registry number: NCT06152237
Countries: Canada, United Kingdom and United States
Participants: Females aged 5–8 years
What is being studied?
This early paediatric study is evaluating the safety and possible effectiveness of a one-time intrathecal dose of TSHA-102, an investigational regulated MECP2 gene therapy.
The study is continuing to follow participants but is not currently recruiting according to ClinicalTrials.gov.
Official study record: https://clinicaltrials.gov/study/NCT06152237
Information checked 3 September 2026. Gene therapy remains experimental, with potential serious and unknown risks. Families should use the official registry for updates and discuss questions with their specialist team.
Registry number: NCT06152237
Countries: Canada, United Kingdom and United States
Participants: Females aged 5–8 years
What is being studied?
This early paediatric study is evaluating the safety and possible effectiveness of a one-time intrathecal dose of TSHA-102, an investigational regulated MECP2 gene therapy.
The study is continuing to follow participants but is not currently recruiting according to ClinicalTrials.gov.
Official study record: https://clinicaltrials.gov/study/NCT06152237
Information checked 3 September 2026. Gene therapy remains experimental, with potential serious and unknown risks. Families should use the official registry for updates and discuss questions with their specialist team.